Research programme: EGFR/HER2 inhibitors - Array BioPharma

Drug Profile

Research programme: EGFR/HER2 inhibitors - Array BioPharma

Latest Information Update: 12 Aug 2011

Price : $50

At a glance

  • Originator Array BioPharma
  • Class
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 10 Aug 2011 No development reported - Preclinical for Cancer in USA (PO)
  • 08 Aug 2005 Array BioPharma has filed an IND with the FDA in the USA for cancer
  • 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top